MOLECULES AND METHODS FOR MODULATING LOW-DENSITY-LIPOPROTEIN RECEPTOR-RELATED PROTEIN 6 (LRP6)
    1.
    发明申请
    MOLECULES AND METHODS FOR MODULATING LOW-DENSITY-LIPOPROTEIN RECEPTOR-RELATED PROTEIN 6 (LRP6) 审中-公开
    用于调节低密度脂蛋白受体相关蛋白6(LRP6)的分子和方法

    公开(公告)号:US20100254980A1

    公开(公告)日:2010-10-07

    申请号:US12740134

    申请日:2008-10-31

    摘要: The invention discloses LRP6 agonizing or antagonizing binding molecules (e.g., antibodies or a Fab fragments), and their use to facilitate or inhibit Wnt pathway signaling, respectively. Said LRP6 agonizing or antagonizing binding molecules can be used to e.g., diagnose, ameliorate the symptoms of, protect against, and treat Wnt signaling disorders associated with aberrantly low or aberrantly high levels of Wnt pathway signaling, respectively. Non-limiting examples of disorders which can be treated associated with aberrant upregulation of Wnt signaling is cancer (e.g., colon cancer). Non-limiting examples of disorders which can be diagnosed, protected against, and treated include cancers, bone disorders (e.g., osteoporosis and osteoarthritis), diabetes, neurodegenerative diseases such as Alzheimer's disease, and fibrotic disorders.

    摘要翻译: 本发明公开了分别促进或抑制Wnt通路信号传导的LRP6激动或拮抗结合分子(例如,抗体或Fab片段)及其用途。 所述LRP6激动或拮抗结合分子可分别用于例如诊断,改善与异常低或异常高水平的Wnt通路信号传导相关的Wnt信号传导障碍的症状,保护和治疗。 可以与Wnt信号传导异常上调相关的病症的非限制性实例是癌症(例如结肠癌)。 可以诊断,保护和治疗的疾病的非限制性实例包括癌症,骨病(例如骨质疏松症和骨关节炎),糖尿病,神经变性疾病如阿尔茨海默病和纤维化病症。

    Antibodies against the tenascin major antigens
    9.
    发明申请
    Antibodies against the tenascin major antigens 审中-公开
    抗腱生蛋白主要抗原的抗体

    公开(公告)号:US20070098715A1

    公开(公告)日:2007-05-03

    申请号:US11391630

    申请日:2006-03-27

    摘要: The invention described herein relates to antibodies directed to the antigen Ten-M2 and uses of such antibodies. In particular, there are provided fully human monoclonal antibodies directed to the antigen Ten-M2. Isolated polynucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions (FR's) and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3, are provided. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies are also provided.

    摘要翻译: 本文描述的本发明涉及针对抗原Ten-M2的抗体和这种抗体的用途。 特别地,提供针对抗原Ten-M2的完全人单克隆抗体。 分离的多核苷酸序列编码和包含重链和轻链免疫球蛋白分子的氨基酸序列,特别是对应于跨越框架区(FR)和/或互补决定区(CDR)的连续重链和轻链序列的序列,特别是FR1至FR4 或CDR1至CDR3。 还提供了表达这种免疫球蛋白分子和单克隆抗体的杂交瘤或其它细胞系。